Acurx Pharmaceuticals Q2 2024 GAAP EPS $(0.26) Misses $(0.21) Estimate
Portfolio Pulse from Benzinga Newsdesk
Acurx Pharmaceuticals (NASDAQ:ACXP) reported a Q2 2024 GAAP EPS of $(0.26), missing the analyst consensus estimate of $(0.21) by 23.81%. This represents a 7.14% improvement over the $(0.28) loss per share from the same period last year.
August 09, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acurx Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.26), missing the analyst consensus estimate of $(0.21) by 23.81%. Despite the miss, the loss per share improved by 7.14% compared to the same period last year.
The earnings miss is likely to negatively impact the stock price in the short term. However, the year-over-year improvement in losses may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100